Related references
Note: Only part of the references are listed.Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma
Tatjana Seitz et al.
SCIENTIFIC REPORTS (2020)
Fibroblast Growth Factor 2 Attenuates Renal Ischemia-Reperfusion Injury via Inhibition of Endoplasmic Reticulum Stress
Xiaohua Tan et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Burden of liver diseases in the world
Sumeet K. Asrani et al.
JOURNAL OF HEPATOLOGY (2019)
Engineered Relaxin as theranostic nanomedicine to diagnose and ameliorate liver cirrhosis
Beata Nagorniewicz et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2019)
Fibroblast growth factor 2 decreases bleomycin-induced pulmonary fibrosis and inhibits fibroblast collagen production and myofibroblast differentiation
Hyun Young Koo et al.
JOURNAL OF PATHOLOGY (2018)
Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo
Deby F. Mardhian et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Fibroblast growth factor 2 (FGF2) regulates cytoglobin expression and activation of human hepatic stellate cells via JNK signaling
Misako Sato-Matsubara et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Fibroblast Growth Factor 2 as an Antifibrotic: Antagonism of Myofibroblast Differentiation and Suppression of Pro-Fibrotic Gene Expression
David M. Dolivo et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2017)
Fibroblast growth factors: key players in regeneration and tissue repair
Luigi Maddaluno et al.
DEVELOPMENT (2017)
Drug targeting to myofibroblasts: Implications for fibrosis and cancer
Saleh Yazdani et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
FGF2 regulates proliferation, migration, and invasion of ECA109 cells through PI3K/Akt signalling pathway in vitro
Hui Shi et al.
CELL BIOLOGY INTERNATIONAL (2016)
Clinical Advancements in the Targeted Therapies against Liver Fibrosis
Ruchi Bansal et al.
MEDIATORS OF INFLAMMATION (2016)
Regulation of Hepatic Stellate Cells and Fibrogenesis by Fibroblast Growth Factors
Justin D. Schumacher et al.
BIOMED RESEARCH INTERNATIONAL (2016)
Magnetic nanoparticle-based drug delivery for cancer therapy
Rainer Tietze et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Low-Molecular-Weight Fibroblast Growth Factor 2 Attenuates Hepatic Fibrosis by Epigenetic Down-Regulation of Delta-Like1
Ruo-Lang Pan et al.
HEPATOLOGY (2015)
The Fibroblast Growth Factor signaling pathway
David M. Ornitz et al.
WILEY INTERDISCIPLINARY REVIEWS-DEVELOPMENTAL BIOLOGY (2015)
Fibroblast growth factor (FGF) signaling in development and skeletal diseases
Chad M. Teven et al.
GENES & DISEASES (2014)
Evolving therapies for liver fibrosis
Detlef Schuppan et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Fibroblast growth factor (Fgf) signaling pathway regulates liver homeostasis in zebrafish
Su-Mei Tsai et al.
TRANSGENIC RESEARCH (2013)
HS-173, a Novel PI3K Inhibitor, Attenuates the Activation of Hepatic Stellate Cells in Liver Fibrosis
Mi Kwon Son et al.
SCIENTIFIC REPORTS (2013)
Basics and recent advances in peptide and protein drug delivery
Benjamin J. Bruno et al.
THERAPEUTIC DELIVERY (2013)
Iron oxide nanoparticles for targeted cancer imaging and diagnostics
Joshua E. Rosen et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2012)
Dextran-Coated Iron Oxide Nanoparticles: A Versatile Platform for Targeted Molecular Imaging, Molecular Diagnostics, and Therapy
Carlos Tassa et al.
ACCOUNTS OF CHEMICAL RESEARCH (2011)
Delivery of Therapeutic Proteins
Dipak S. Pisal et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Fibroblast Growth Factors: Biology, Function, and Application for Tissue Regeneration
Ye-Rang Yun et al.
Journal of Tissue Engineering (2010)
Mechanisms of hepatic fibrogenesis
Scott L. Friedman
GASTROENTEROLOGY (2008)
Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver
Scott L. Friedman
PHYSIOLOGICAL REVIEWS (2008)
Magnetic nanoparticles for drug delivery
Manuel Arruebo et al.
NANO TODAY (2007)
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma
Elisa Wurmbach et al.
HEPATOLOGY (2007)
Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis
CD Yu et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease
MA Bush et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity
AN Plotnikov et al.
CELL (2000)
Share Paper
